Recombinant DNA (rDNA) refers to artificial DNA molecules that are created by combining genetic material from different sources. This technology involves the insertion of DNA fragments from one ...
According to Research by SNS Insider, the U.S. Peptide Therapeutics Market is Set to Reach USD 35.71 Billion by 2032, Supported by Rising Adoption of Precision Biologics and Advances in Peptide ...
Recombinant antibody technology has been leveraged to mitigate a range of common problems associated with hybridoma platforms, helping to facilitate the development of an entirely new class of ...
Chaudhary Sarwan Kumar Himachal Pradesh Krishi Vishvavidyalaya, Palampur, successfully concluded a two-day workshop on ...
The development of early monoclonal antibody (mAb) therapies centered around the hybridoma platform requires the production of target antigen or immunogen and animal immunizations. This means there ...
- EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system. It serves as a comprehensive solution for the development and manufacturing of ...
The protein, reverse transcriptase, has become an essential tool for making DNA copies of RNA.
Cornell researchers have found that a new DNA sequencing technology can be used to study how transposons move within and bind ...
In September, David Baltimore — the scientist who discovered reverse transcriptase, a breakthrough often described as one of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback